ArticleOpen life sciences2026
Norepinephrine promotes lung cancer cell progression via PFKFB3-promoted histone lactylation-mediated activation of the NF-κB signaling pathway.
Article in Open life sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- TRIM47 promotes cell viability, cell cycle progression, metabolic reprogramming, and inhibits apoptosis of glioma via the NF-κB signaling pathway.Translational cancer research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aims to investigate molecular mechanisms by which norepinephrine (NE) exposure influences lung cancer cell behavior, identify key factors and pathways involved in stress-related signaling in lung cancer cells. NE was used to treat lung cancer cells (H1975) to simulate a stress-related signaling environment. PFKFB3 mRNA expression and phosphorylation levels of epithelial-mesenchymal transition (EMT) markers and key proteins in NF-κB signaling pathway were evaluated. NE significantly enhanced lung cancer cell proliferation, specifically upregulated PFKFB3 mRNA expression, promoted EMT marker (N-cadherin and Vimentin) expression, and increased cell migration capacity. Knockdown of PFKFB3 or inhibition of glycolysis reduced cell viability, lactate production, ATP levels, and expression of glycolysis-related enzymes (LDHA and GLUT1) and EMT markers, while suppressing cell migration. Combined interventions exhibited synergistic inhibitory effects. Mechanistic studies revealed that PFKFB3 knockdown inhibited phosphorylation of NF-κB pathway proteins (IKKβ, IκBα, and p65), blocked pathway activation, and reduced histone lactylation levels, particularly at the H4K12la modification site. These effects were reversed by NE intervention. This study suggests a mechanism whereby NE upregulates PFKFB3, activates glycolysis, promotes lactate production to drive histone lactylation, and activates the NF-κB signaling pathway, which is associated with EMT and cell migration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.